We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Hormone Levels Alter CVD Risk in Older Women

By LabMedica International staff writers
Posted on 13 Jun 2018
Print article
Image: Testosterone/estradiol ratio and the risk of cardiovascular disease, coronary heart disease and heart failure (HF) in post-menopausal women (Photo courtesy of Johns Hopkins Medicine).
Image: Testosterone/estradiol ratio and the risk of cardiovascular disease, coronary heart disease and heart failure (HF) in post-menopausal women (Photo courtesy of Johns Hopkins Medicine).
Higher androgen and lower estrogen levels are associated with cardiovascular disease (CVD) risk factors in women; however, studies on sex hormones and incident CVD events in women have yielded conflicting results.

Studies have shown that, prior to menopause, women have lower heart disease rates than men, and because estrogen levels drop sharply after menopause, physicians once thought that replacing estrogen would reduce cardiovascular disease risk. Other studies have shown replacement female hormones were not necessarily protective and could possibly raise the risk of strokes, blood clots and heart disease.

A team of scientists working with Johns Hopkins Medicine (Baltimore, MD, USA) analyzed data from 2,834 postmenopausal women who had participated in the federally funded Multi-Ethnic Study of Atherosclerosis (MESA). Participants were a mean age of 65 at the start of the study, and 38% white, 28% African-American, 22% Hispanic and 12% Chinese-American. At an initial visit that took place between 2000 and 2002, scientists took blood samples and measured levels of testosterone and estradiol.

Over 12 years of follow up, the women had 283 instances of cardiovascular disease, including 171 instances of coronary heart disease and heart attacks, 88 strokes and 103 instances of heart failure as determined by medical records, hospitalizations, telephone interviews and death certificates. When team compared testosterone and estradiol levels to instances of heart and cardiovascular diseases, they found, in general, that higher testosterone was associated with increased risk and higher estradiol levels with lower risk. For every standardized unit increase in the ratio of testosterone to estrogen, there was a 19% increase in cardiovascular disease risk, a 45% increase in coronary heart disease risk and a 31% increase in heart failure risk.

Erin D. Michos, MD, MHS, associate professor of medicine and a senior author of the study, said, “A woman's sex hormone levels and ratios of them isn't something that physicians regularly check. Because an imbalance in the proportion of testosterone (the main male sex hormone) to estrogen (the main female sex hormone) may affect heart disease risk, physicians may want to think about adding hormone tests to the toolbox of screenable risk factors, like blood pressure or cholesterol, to identify women who may be at higher risk of heart or vascular disease.” The study was published in the June 2018 issue of the Journal of the American College of Cardiology.

Related Links:
Johns Hopkins Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.